NL-OMON46209已完成不适用
Safety and protective efficacy of genetically attenuated Pf*b9*slarp (PfSPZ-GA1) malaria parasites in healthy volunteers - GA1
Sanaria0 个研究点目标入组 67 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 67
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subject is aged * 18 and * 35 years and in good health.
- •2. Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
- •3. Subject is able to communicate well with the investigator, is available to attend all study visits.
- •4. Furthermore the subject will remain within the Netherlands from day -1 till day +28 after each parasite exposure and be reachable by phone (24/7). From day 28 till day 35 after each infection subjects have to be reachable by phone (24/7) throughout this study period.
- •5. Subject agrees to inform his/her general practitioner about participation in the study and to sign a request to release by the GP, and medical specialist when necessary, any relevant medical information concerning possible contra-indications for participation in the study.
- •6. Subject agrees to refrain from blood donation to Sanquin or for other purposes throughout the study period and for a defined period thereafter according to current Sanquin guidelines (3 years minimum, depending on serology).
- •7. Non-pregnant, non-lactating females of reproductive potential (i.e., have a uterus and are neither surgically sterilized nor post-menopausal) should agree to use adequate contraception and not to breastfeed for the duration of study.
- •8. Subject agrees to refrain from intensive physical exercise (disproportionate to the subjects* usual daily activity or exercise routine) for twenty-one days following each immunization and during the malaria challenge period.
- •9. Subject has signed informed consent.
排除标准
- •1. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, psychiatric or other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:
- •1.1 Body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening
- •1.2 A heightened risk of cardiovascular disease, defined as: an estimated ten year risk of fatal cardiovascular disease of *5% at screening, as determined by the Systematic Coronary Risk Evaluation (SCORE); history, or evidence at screening, of clinically significant arrhythmia*s, prolonged QT-interval or other clinically relevant ECG abnormalities; or a positive family history of cardiac events in first or second degree relatives (according to the system used in medical genetics) <50 years old.
- •1.3 Functional asplenia, sickle cell trait/disease, thalassaemia trait/disease or G6PD deficiency.
- •1.4 History of non-febrile seizure at any time prior to study onset, even if no longer on medication
- •1.5 Positive HIV, HBV or HCV screening tests.
- •1.6 Chronic use of i) immunosuppressive drugs, ii) antibiotics, iii) or other immune modifying drugs within three months prior to study onset (excluding inhaled and topical corticosteroids and incidental use of oral anti-histamines) or expected use of such during the study period.
- •1.7 History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past five years.
- •1.8 Any history of treatment for severe psychiatric disease by a psychiatrist in the past year.
- •1.9 History of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset, positive urine toxicology test for cocaine or amphetamines at screening or prior to infection or positive urine toxicology test for cannabis at baseline prior to infection.
- •2. For female subjects: positive urine pregnancy test at screening or prior to immunization or prior to infection.
- •3. Any history of malaria, positive serology for P. falciparum, or previous participation in any malaria (vaccine) study.
- •4. Known hypersensitivity to or contra-indications (including co-medication) for use of atovaquone, proguanil or artemether-lumefantrine, or history of severe (allergic) reactions to mosquito bites.
- •5. Receipt of any vaccinations in the 3 months prior to the start of the study or plans to receive any other vaccinations during the study period or up to 8 weeks thereafter.
- •6. Participation in any other clinical study in the 30 days prior to the start of the study or during the study period.
- •7. Being an employee or student of the department of Medical Microbiology or Infectious Diseases of the Radboudumc or the LUMC.
- •8. Any other condition or situation that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
研究者
相似试验
已完成
不适用
Safety and protective efficacy of genetically modified Plasmodium berghei (Pb(PfCS@UIS4)) malaria parasites in healthy volunteersPlasmodium falciparum10037072MalariaNL-OMON45576Radboud Universitair Medisch Centrum30
已完成
不适用
Safety and preliminary protective efficacy of genetically attenuated Pf*mei2 (GA2) malaria parasites in healthy Dutch volunteersparasitaire ziekte10037072MalariaNL-OMON51062eids Universitair Medisch Centrum51
已完成
1 期
Genetically Attenuated Malaria Parasite as potential vaccine candidate against malaria infectionmalariaACTRN12617000824369QIMR Berghofer Medical Research Institute6
已完成
2 期
ior ®EPOCIM as a cardioprotective agent in the surgery of rheumatic valvular disease.Rheumatic valvular diseaseRPCEC00000165Center of Molecular Immunology (CIM), Havana30
已完成
3 期
?Determining efficacy and safety of recombinant growth hormone Somatin® (AryaTinaGene) compared to Norditropin® (Novonordisk) in children with growth hormone deficiencyIRCT20171122037571N1Arya Tina Gene company80